EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

Dec 6th, 2018 - The EUTOS long-term survival score (ELTS) better discriminates patients for risk stratification than the standard Sokal score, according to findings from an analysis of data from 904 patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) who had enrolled in 6 multicenter studies.

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma

Dec 5th, 2018 - The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

Rivaroxaban may reduce VTE risk in cancer patients

Dec 5th, 2018 - The CASSINI trial evaluates VTE prophylaxis in ambulatory patients receiving systemic therapy.

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

Dec 5th, 2018 - Adding daratumumab to standard treatment with lenalidomide and dexamethasone (DRd) reduced the risk of progression or death by 44% among patients with transplant-ineligible newly-diagnosed multiple myeloma, according to an interim analysis of data from the randomized, open-label, multicenter phase 3 MAIA clinical trial

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL

Dec 5th, 2018 - The combination of ibrutinib and rituximab provided superior progression-free survival and, after follow-up, superior overall survival, compared with the current standard of care, chemoimmunotherapy (CIT) fludarabine, cyclophosphamide, and rituximab (FCR), in treatment-naive patients younger than 70 years with chronic lymphocytic leukemia (CLL), according to research presented at a late-breakin...

Another Rituximab Biosimilar Passes Lymphoma Test

Dec 5th, 2018 - A rituximab biosimilar demonstrated noninferiority to European (EU)-licensed rituximab (MabThera) in a randomized trial involving patients with low-tumor burden follicular lymphoma

Ibrutinib Plus Rituximab vs Standard Chemoimmunotherapy in Younger Patients With Treatment-Naive CLL

Dec 4th, 2018 - A 6-month course of chemotherapy-based treatment with FCR (intravenous fludarabine and cyclophosphamide plus rituximab [Rituxan]) has historically been the most effective treatment for chronic lymphocytic leukemia (CLL), especially in patients 70 years of age and younger.

Researchers Identify Mutation in BCL2 Protein That Causes Resistance to Venetoclax in Progressive CLL

Dec 4th, 2018 - Investigators from Australia have identified a genetic mutation that causes resistance to the targeted drug venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL)

Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients

Dec 4th, 2018 - Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment.

Cancer-VTE Trial Falls Short

Dec 4th, 2018 - A closely watched trial of venous thromboembolism (VTE) prevention with an oral anticoagulant in cancer patients fell short of a clear win, but not because the drug didn't work, according to a report here.

Laurie H. Sehn, MD, MPH, on DLBCL: Trial Results on the Prognostic Significance of MYC

Dec 4th, 2018 - Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses a study by the Lunenburg Lymphoma Biomarker Consortium

Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study

Dec 4th, 2018 - Results from the randomized, phase 3b superiority study, CASSINI, on rivaroxaban thromboprophylaxis in high-risk patients who received systemic therapy, were revealed during a late-breaking abstract session at the 2018 American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.1 The investigators determined that rivaroxaban, which is not yet approved in this set...

Durable Remissions Sustained at 2-Year Follow-Up of Axi-Cel in Large B-Cell Lymphomas

Dec 3rd, 2018 - Two-year findings from the ZUMA-1 trial showed an overall survival (OS) rate of more than 50% from treatment with axicabtagene ciloleucel (axi-cel), a CD19-targeted CAR T-cell therapy in patients with refractory large B cell lymphoma; the median OS had not yet been reached. These data, representing a clear plateau in the survival curve, were presented at the 2018 ASH Annual Meeting and also pub...

Cancer patients show reduced risk of harmful clots while taking direct oral anticoagulants

Dec 3rd, 2018 - A new study suggests taking a DOAC) can reduce the risk of harmful blood clots in patients undergoing cancer treatments without substantially increasing the risk of bleeding problems.

Ibrutinib-based therapy more effective, safer in younger patients with previously untreated CLL compared with current standard of care

Dec 3rd, 2018 - A six-month course of chemotherapy-based treatment with intravenous fludarabine and cyclophosphamide plus rituximab (FCR) has historically been the most effective treatment for chronic lymphocytic leukaemia (CLL), especially in patients 70 years of age and younger.

Combination Regimen Extends PFS in Myeloma

Dec 3rd, 2018 - Older transplant-ineligible patients with newly diagnosed multiple myeloma had significant improvement in progression-free survival (PFS) with the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), according to the randomized MAIA trial reported here.

Axi-Cel Efficacy Persists at 2-Year Assessment for Large B-Cell Lymphoma

Dec 3rd, 2018 - Axicabtagene ciloleucel (axi-cel) elicited a 2-year overall survival (OS) rate of 51% in patients with refractory large B cell lymphoma, representing a clear plateau in the survival curve, according to long-term findings from the ZUMA-1 trial presented at the 2018 ASH Annual Meeting and published in Lancet Oncology

Emapalumab safe, effective in pediatric primary hemophagocytic lymphohistiocytosis

Dec 3rd, 2018 - Emapalumab, an interferon gamma-blocking antibody, controls disease activity and has a favorable safety profile in patients with primary hemophagocytic lymphohistiocytosis (HLH)